person · Reporting owner

Brege Laura

Disclosed activity across 7 companies

Tapewire entity: 37268
SEC CIK: 0001365619

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACADIA PHARMACEUTICALS INCACAD · Entity 3913	Director	May 29, 2026	June 01, 2026
ARATANA THERAPEUTICS, INC.PETX · Entity 155913	Director	July 27, 2018	July 30, 2018
DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930	Director	May 30, 2019	May 31, 2019
Edgewise Therapeutics, Inc.EWTX · Entity 3965	Director	June 05, 2026	June 17, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	Director	June 15, 2026	June 18, 2026
Pacira BioSciences, Inc.PCRX · Entity 4928	Director	June 10, 2026	June 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date May 29, 2026 · Filed June 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,202	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 23,202 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	9,311	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28	Direct	16,004	Reported balance After 2026-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.

F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.

ARATANA THERAPEUTICS, INC.

Report date July 27, 2018 · Filed July 30, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,500	Reported balance After 2018-07-27 transaction · row 1 1 source row Row 1 · 2018-07-27 · Grant · Acquired 4,500 · Balance 13,500
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2028-07-26	Direct	7,500	Reported balance After 2018-07-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-07-27 · Grant · Acquired 7,500 · Balance 7,500 F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date.

DYNAVAX TECHNOLOGIES CORP

Report date May 30, 2019 · Filed May 31, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2026-05-29	Direct	15,000	Reported balance After 2019-05-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-30 · Grant · Acquired 15,000 · Balance 15,000 F2: Not applicable. F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date.

F2: Not applicable.

Edgewise Therapeutics, Inc.

Report date June 05, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05	Direct	16,377	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Mirum Pharmaceuticals, Inc.

Report date June 15, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14	Direct	3,772	Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	1,980	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.

Pacira BioSciences, Inc.

Report date June 10, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,120	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 30,120 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10	Direct	10,891	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 2 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 44,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F4: In connection with the Merger, these options were accelerated and canceled without payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 18, 2026 00:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantDeferred Stock Units · Derivative	1,980	$0.00	$0.00	Disclosure SEC source: 0001365619-26-000005 · form4-06172026_080608.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document
June 15, 2026 Filed Jun 18, 2026 00:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	3,772	$0.00 Strike: $101.00	$0.00	Disclosure SEC source: 0001365619-26-000005 · form4-06172026_080608.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:06 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	10,891	$0.00 Strike: $23.42	$0.00	Disclosure SEC source: 0001628280-26-043002 · wk-form4_1781312808.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:06 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	6,405	$0.00	$0.00	Disclosure SEC source: 0001628280-26-043002 · wk-form4_1781312808.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,120 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 05, 2026 Filed Jun 17, 2026 21:14 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	16,377	$0.00 Strike: $35.59	$0.00	Disclosure SEC source: 0001365619-26-000004 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document
May 29, 2026 Filed Jun 1, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	9,311	$0.00	$0.00	Disclosure SEC source: 0001365619-26-000002 · form4-06012026_060608.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. Read SEC document
May 29, 2026 Filed Jun 1, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	16,004	$0.00 Strike: $21.66	$0.00	Disclosure SEC source: 0001365619-26-000002 · form4-06012026_060608.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document
May 29, 2026 Filed Jun 1, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	8,107	$0.00	$0.00	Disclosure SEC source: 0001365619-26-000002 · form4-06012026_060608.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document
May 29, 2026 Filed Jun 1, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	8,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001365619-26-000002 · form4-06012026_060608.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001415889-25-024463 · form4-09122025_080904.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2029-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,491	$75.07	$111,929.37	Disclosure SEC source: 0001415889-25-024463 · form4-09122025_080904.xml · nonDerivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,703 F2 · price: The weighted average sale price for the transaction reported was $75.07, and the range of prices were between $74.745 and $75.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	15,509	$74.34	$1,152,939.06	Disclosure SEC source: 0001415889-25-024463 · form4-09122025_080904.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,194 F1 · price: The weighted average sale price for the transaction reported was $74.34, and the range of prices were between $73.73 and $74.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
September 11, 2025 Filed Sep 13, 2025 00:00 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	17,000	$15.00	$255,000.00	Disclosure SEC source: 0001415889-25-024463 · form4-09122025_080904.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2025 Filed Jun 18, 2025 23:37 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $14.68	$0.00	Disclosure SEC source: 0001562180-25-004961 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:17 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	11,279	$0.00 Strike: $24.34	$0.00	Disclosure SEC source: 0001396814-25-000080 · wk-form4_1749845835.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:17 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	6,163	$0.00	$0.00	Disclosure SEC source: 0001396814-25-000080 · wk-form4_1749845835.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,715 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 04, 2025 Filed Jun 5, 2025 22:01 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	14,446	$21.78	$314,633.88	Disclosure SEC source: 0001415889-25-015832 · form4-06052025_060604.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,095 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.77 through $21.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document
May 29, 2025 Filed Jun 2, 2025 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	8,107	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015270 · form4-06022025_060601.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document
May 29, 2025 Filed Jun 2, 2025 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	13,793	$0.00 Strike: $22.29	$0.00	Disclosure SEC source: 0001415889-25-015270 · form4-06022025_060601.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document
May 29, 2025 Filed Jun 2, 2025 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	9,387	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015270 · form4-06022025_060601.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document
May 29, 2025 Filed Jun 2, 2025 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	9,387	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-015270 · form4-06022025_060601.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
May 29, 2025 Filed Jun 2, 2025 23:36 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantDeferred Stock Units · Derivative	3,977	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015303 · form4-06022025_110641.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Underlying: Common Stock · 3,977 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F4 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F4 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document
May 29, 2025 Filed Jun 2, 2025 23:36 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	6,268	$0.00 Strike: $44.00	$0.00	Disclosure SEC source: 0001415889-25-015303 · form4-06022025_110641.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,268 Underlying: Common Stock · 6,268 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document
May 29, 2025 Filed Jun 2, 2025 23:36 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	5,703	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015303 · form4-06022025_110641.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document
May 29, 2025 Filed Jun 2, 2025 23:36 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	5,703	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-015303 · form4-06022025_110641.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
August 16, 2024 Filed Aug 19, 2024 12:25 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	PurchaseCommon Stock	1,000	$12.81	$12,810.00	Disclosure SEC source: 0001396814-24-000117 · wk-form4_1724070340.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,552 Read SEC document
June 12, 2024 Filed Jun 13, 2024 22:12 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	12,179	$0.00 Strike: $28.68	$0.00	Disclosure SEC source: 0001396814-24-000073 · wk-form4_1718316748.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document
June 12, 2024 Filed Jun 13, 2024 22:12 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	5,230	$0.00	$0.00	Disclosure SEC source: 0001396814-24-000073 · wk-form4_1718316748.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,552 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 10, 2024 Filed Jun 12, 2024 23:25 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	20,594	$0.00 Strike: $17.13	$0.00	Disclosure SEC source: 0001562180-24-005019 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,594 Underlying: Common Stock · 20,594 shares Expires 2034-06-10 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the 2025 annual meeting of stockholders. Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:22 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	5,703	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016068 · form4-06072024_100651.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document
June 05, 2024 Filed Jun 7, 2024 22:22 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	8,779	$0.00 Strike: $26.30	$0.00	Disclosure SEC source: 0001415889-24-016068 · form4-06072024_100651.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,779 Underlying: Common Stock · 8,779 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting. Read SEC document
May 29, 2024 Filed May 31, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	9,387	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015084 · form4-05312024_060502.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document
May 29, 2024 Filed May 31, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	15,959	$0.00 Strike: $14.62	$0.00	Disclosure SEC source: 0001415889-24-015084 · form4-05312024_060502.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document
May 29, 2024 Filed May 31, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	6,652	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015084 · form4-05312024_060502.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document
May 29, 2024 Filed May 31, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	6,652	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015084 · form4-05312024_060502.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:26 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	12,925	$0.00 Strike: $38.74	$0.00	Disclosure SEC source: 0001209191-23-038014 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2033-06-14 Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:26 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	1,775	$0.00	$0.00	Disclosure SEC source: 0001209191-23-038014 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,322 F1 · shares: Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 12, 2023 Filed Jun 14, 2023 21:14 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	4,500	$24.87	$111,906.00	Disclosure SEC source: 0001209191-23-037106 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,502 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.68 through $25.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document
June 12, 2023 Filed Jun 14, 2023 21:45 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $28.97	$0.00	Disclosure SEC source: 0001209191-23-037127 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting. Read SEC document
June 12, 2023 Filed Jun 14, 2023 23:29 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	22,123	$0.00 Strike: $9.55	$0.00	Disclosure SEC source: 0001562180-23-005174 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,123 Underlying: Common Stock · 22,123 shares Expires 2033-06-12 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders. Read SEC document
June 05, 2023 Filed Jun 8, 2023 01:18 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	600	$38.74	$23,244.00	Disclosure SEC source: 0001209191-23-035254 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document
June 01, 2023 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	6,652	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · derivative · entry 8 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 01, 2023 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	11,045	$0.00 Strike: $23.90	$0.00	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · derivative · entry 7 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-05-31 F3 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 01, 2023 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	8,552	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · derivative · entry 6 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 01, 2023 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	8,552	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · nonDerivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:34 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $29.90	$0.00	Disclosure SEC source: 0001209191-23-023336 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · derivative.exercise_date: The option vested in 12 equal monthly installments, provided that the reporting person remained in continuous service with the issuer through each vesting date, and became fully exercisable on June 12, 2014. Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:34 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	7,000	$40.72	$285,040.00	Disclosure SEC source: 0001209191-23-023336 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,147 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:34 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	7,000	$29.90	$209,300.00	Disclosure SEC source: 0001209191-23-023336 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document
January 12, 2023 Filed Jan 17, 2023 22:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $17.01	$0.00	Disclosure SEC source: 0001209191-23-003554 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
January 12, 2023 Filed Jan 17, 2023 22:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	12,500	$18.25	$228,125.00	Disclosure SEC source: 0001209191-23-003554 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.